ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
The drug services firm Sterling Pharma Solutions and the Manchester Institute of Biotechnology (MIB) plan to scale up a low-cost route to molnupiravir, a Merck & Co. antiviral recently approved in the UK to treat COVID-19. The route, developed by MIB with funding from the Bill and Melinda Gates Foundation, uses a novel enzyme, cytidine aminotransferase, which is expected to lower production costs. At its site in Dudley, England, Sterling plans to produce multikilogram quantities of molnupiravir for generic drug firms that will make pills for low-income countries.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X